|Bid||109.05 x 2200|
|Ask||109.16 x 900|
|Day's range||108.31 - 109.22|
|52-week range||79.11 - 121.53|
|Beta (5Y monthly)||0.83|
|PE ratio (TTM)||29.43|
|Earnings date||29 Oct 2021|
|Forward dividend & yield||5.20 (4.76%)|
|Ex-dividend date||14 Oct 2021|
|1y target est||127.01|
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
J&J (JNJ) beats estimates for earnings but misses the same for sales. FDA authorizes mix and match of COVID vaccine boosters.
Resmed (NYSE: RMD), Walgreens Boots Alliance (NASDAQ: WBA) and AbbVie (NYSE: ABBV) are profitable companies that have clear paths to future revenue growth. ResMed is already an industry leader in sleep apnea therapies, an area that's expected to grow as our population ages. Walgreens Boots Alliance is jumping onto the trend toward value-oriented healthcare services, and AbbVie's huge stable of drugs and pipeline give it a diversity that protects its long-term outlook.